MBRX prices $9.3M offering: 12.38M shares (or pre-funded warrants) + 37.13M warrants
AI Summary
Moleculin priced a best-efforts public offering of 12,376,667 shares of common stock (or pre-funded warrants in lieu thereof) with detachable Common Warrants to purchase up to 37,130,001 shares at a combined price of $0.75, implying gross proceeds of about $9.3M. The Common Warrants are immediately exercisable at $0.75, expire five years after issuance, and the offering is expected to close on or about August 3, 2026, subject to customary closing conditions; Roth Capital is the exclusive placement agent. Timing: The press release does not indicate dilution today; initial share dilution occurs at the offering close (Aug 3, 2026), and once the offering closes those shares have been issued.
Positives
- Gross proceeds expected ≈ $9.3M
Negatives
- Very warrant-heavy deal: up to 37.13M warrants (3 warrants per share) creates large potential future dilution
- Warrants are immediately exercisable at the same $0.75 price, creating immediate overhang if exercised
- Offering is best-efforts (not firm commitment), so actual proceeds could be uncertain until close
Filing Context
Filing and Dilution Context
Earliest dilution
Earliest dilution: Aug 3, 2026 close
Dilution status
delayed
Dilution timing
Dilution status: Delayed
Trigger type
closing
Trigger date
Aug 3, 2026